RENEWED APPROACH TO THE TREATMENT OF THE GOUT IN FEMALE

Given the central role of hyperuricemia in the pathophysiology of gout, urate lowering therapies, including xanthine oxidase inhibitors, uricosuric agents, and uricases, are employed with the goal of preventing flares, which in turn are most commonly managed with nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, glucocorticoids, or anti-IL-1β agents. Despite the availability of effective urate-lowering drugs, treatment of gout is often one of the most difficult problems to solve. Aim of the study. To conduct a comparative analysis of hypouricemic drugs in patients with gout. Materials and methods. The study included 55 female patients with a definite diagnosis of gout who applied to the arthrological department on the basis of the multidisciplinary clinic of the Tashkent Medical Academy for the purpose of therapy correction. Allopurinol was used as urate-lowering therapy at a starting dose of 100 mg/day, followed by an increase by 100 mg/day every 2–3 weeks until the target UA level was achieved. In cases of ineffectiveness of the maximum possible doses of allopurinol and/or the presence of adverse reactions associated with this drug, febuxostat was prescribed at an initial dose of 80 mg/day, which, if necessary, was increased to 120 mg/day. Results and discussion. Adherence to regular drug therapy among patients with gout receiving allopurinol was 25% at a high level, 40% at an average level, and 35% at a low level. When using febuxostat, high adherence to therapy was detected in more than 50% of cases. Adherence to high-level lifestyle changes was 30%, medium 40%, low - 30%, and readiness to correct hypouricemic therapy was 38%, 45% and 17%, respectively, by level. Conclusion. Thus, compliance with recommendations for the management of patients with gout allows for high patient adherence to both drug treatment and lifestyle changes.